In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors

This publication has 21 references indexed in Scilit:

• Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors
  Journal of Clinical Oncology, 2001
• Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
  European Journal Of Cancer, 2001
• Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
  Proceedings of the National Academy of Sciences, 2000
• Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
  Proceedings of the National Academy of Sciences, 2000
• High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer
  Annals of Oncology, 1999
• In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells
  British Journal of Cancer, 1998
• In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
  Annals of Oncology, 1998
• NMR-Based Model of an Ecteinascidin 743−DNA Adduct
  Journal of the American Chemical Society, 1997
• DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean Tunicate Ecteinascidia turbinata
  Biochemistry, 1996
• Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743)
  Drugs of the Future, 1996